Charlie Scott

6PUBLICATIONS

32CO-AUTHORS

Epidemiological modellingSport and exercise nutritionBehavioural epidemiologyCharacterisation of biological macromoleculesEconomic models and forecasting

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jun 05, 2026

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

|Apr 24, 2026

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.

|Mar 29, 2026

Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

Rajiv Agarwal, Ricardo Correa-Rotter, Sankar D Navaneethan

|Nov 06, 2025

Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.

Amy Mottl, Charlie Scott, Jennifer B Green

|Sep 18, 2025

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.

Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink

|May 02, 2025

Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.

Peter Rossing, Andreas L Birkenfeld, Paola Fioretto

Pageof 1

Frequent Collaborators

Peter Rossing

Janet B McGill

Hiddo J L Heerspink

Muthiah Vaduganathan

Julio Rosenstock

Masaomi Nangaku

Jennifer B Green

Amy Mottl

Rajiv Agarwal

Johannes F E Mann

Frequent Collaborators

Peter Rossing

Janet B McGill

Hiddo J L Heerspink

Muthiah Vaduganathan